

September 17, 2007



Oculus Innovative Sciences Microcyn Technology Data to be Presented by Researchers at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced today that five posters on selected studies assessing the anti-infective nature of Microcyn(R) Technology were accepted for presentation at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at McCormick Place in Chicago, September 17 - 20. ICAAC, a key scientific event, attracts scientists from around the world to discuss important themes and present the newest treatment advances in infectious disease. Oculus Innovative Sciences will also have a presence with a scientific exhibit at booth #554 located in the exhibit hall at McCormick Place/Lakeside Center. The Oculus booth will provide additional information to prospective investigators for its upcoming Phase III trials.

The poster presentations will discuss:

1. Super-Oxidized Solution (SOS) Therapy for Diabetic Foot Ulcers
2. Effects of pH Neutral, Super-Oxidized Solution on Human Dermal Fibroblasts In Vitro
3. The Anti-Viral Efficacy of a New Super-Oxidized Solution
4. The Anti-Bacterial Efficacy of a New Super-Oxidized Solution
5. Activity of a pH Neutral Super-Oxidized Solution Against Bacteria Selected for Sodium Hypochlorite Resistance Bacteria Selected for Sodium Hypochlorite Resistance

Oculus president and CEO, Hoji Alimi, will also conduct a conference call on Monday, September 17, 2007 at 9:00 a.m. (EDT) from ICAAC to update investors on the company's Phase II study evaluating the use of the company's flagship Microcyn(R) Technology on mildly infected diabetic foot ulcers. To participate in the conference call, please call 1-877-407-4018 (domestic/toll-free) or 1-201-689-8471 (international). A telephone replay will be available for 48 hours after the call at 1-877-660-6853 (domestic/toll-free), or 1-201-612-7415 (international). Please enter account number 3055 and conference identification number 255635.

About ICAAC

The American Society for Microbiology (ASM) is hosting the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which will be held in Chicago, Illinois, September 17 - 20, 2007. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the challenges of infectious diseases.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated significant wound healing in chronic and acute wounds. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, some matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about our ability to replicate the results of the test in clinical trials, if at all, or for such trials or other tests to establish the conclusions suggested by the results of the test. These forward-looking statements are identified by the use of words such as "believe" "suggest," "could involve," "could be considered," "intended," "goal" and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, risks that revenues will not reach expected levels, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended June 30, 2007 and Form 10-K for the fiscal year ended March 31, 2007. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.

Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.

Source: Oculus Innovative Sciences, Inc.